AngioDynamics, Inc. (NASDAQ:ANGO) Receives Consensus Rating of “Hold” from Analysts

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have earned an average rating of “Hold” from the five ratings firms that are covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have given a buy rating and one has given a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $19.50.

Several equities analysts have recently issued reports on ANGO shares. HC Wainwright lifted their price objective on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Canaccord Genuity Group upped their target price on shares of AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Wall Street Zen upgraded shares of AngioDynamics from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Zacks Research cut shares of AngioDynamics from a “hold” rating to a “strong sell” rating in a report on Thursday, July 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th.

Insider Activity at AngioDynamics

In other news, SVP Warren Jr sold 23,370 shares of the firm’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in AngioDynamics in the second quarter valued at $49,480,000. Armistice Capital LLC boosted its position in shares of AngioDynamics by 3.9% during the 4th quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock worth $21,828,000 after acquiring an additional 64,000 shares in the last quarter. Weber Capital Management LLC ADV acquired a new position in shares of AngioDynamics during the 2nd quarter worth about $17,649,392. Royce & Associates LP increased its holdings in shares of AngioDynamics by 27.3% in the 4th quarter. Royce & Associates LP now owns 1,267,451 shares of the medical instruments supplier’s stock valued at $16,274,000 after acquiring an additional 272,091 shares during the last quarter. Finally, Bastion Asset Management Inc. increased its holdings in shares of AngioDynamics by 17.4% in the 1st quarter. Bastion Asset Management Inc. now owns 1,313,002 shares of the medical instruments supplier’s stock valued at $14,107,000 after acquiring an additional 194,822 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Trading Down 1.5%

AngioDynamics stock opened at $15.28 on Friday. The firm has a market capitalization of $631.52 million, a P/E ratio of -17.56 and a beta of 0.33. AngioDynamics has a twelve month low of $9.39 and a twelve month high of $16.29. The stock’s fifty day simple moving average is $15.23 and its 200-day simple moving average is $12.83.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.The firm had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Sell-side analysts predict that AngioDynamics will post -0.25 earnings per share for the current year.

About AngioDynamics

AngioDynamics, Inc (NASDAQ: ANGO) is a medical technology company that develops and manufactures minimally invasive devices used in vascular, oncology, and surgical procedures. Its products are designed to help physicians diagnose and treat vascular disease, remove or manage blood clots, and deliver targeted therapies for certain cancers and other conditions.

The company’s product portfolio includes the Auryon Atherectomy System for treating peripheral arterial disease, the AngioVac System for the removal of unwanted intravascular material, and the NanoKnife System, which uses irreversible electroporation to ablate soft-tissue tumors.